Comparison of EFS rates. Comparison of EFS rates for infants with MLL⁺ ALL by remission status at the time of HSCT (A) and by the source of donor cells (B). Patients receiving transplants in first remission fared significantly better than those undergoing HSCT at other times (3-year posttransplantation EFS, 64.4% versus 22.2%, P = .004). There was no statistically appreciable difference in outcome between patients receiving cord blood or non–cord blood in first remission. Tick marks represent patients still at risk of death or other adverse events.